Category: cancer biology

Misidentified cell line fells cancer paper

Screen Shot 2016-04-15 at 2.52.06 PMResearchers have retracted a paper about a new molecular target for cancer after realizing they had mistaken the identity of their cell line.

It’s all too easy to mix up cell lines, so we see plenty of retractions for that reason — and, according to an expert in the area, many more cases lurk uncorrected in the literature.

The retraction notice for “Knockdown of tumor protein D52-like 2 induces cell growth inhibition and apoptosis in oral squamous cell carcinoma” in Cell Biology International explains the authors’ perspective on this case:

Continue reading Misidentified cell line fells cancer paper

Author denies accusations of blatant duplication

NPGTwitter is abuzz today over allegations that a recent paper in Scientific Reports contains a blatant example of duplication.

According to the allegations, a group of researchers in Malaysia have used the same four images to represent some 30 cells at different stages of cell death. One researcher has even suggested the allegedly doctored images appear in three different papers.

Is this a manipulated image? See for yourself:

Continue reading Author denies accusations of blatant duplication

JAMA takes all calls for retraction seriously — even from PETA

JAMAA leading medical journal is taking a second look at a recent high-profile paper about elephants’ lower risk of cancer, after receiving a call for retraction from a somewhat unusual corner: the animal rights group PETA.

This isn’t the first time the activist group has called for a retraction — last year, it nudged a journal to pull a paper that had been flagged for fraud by the U.S. Office of Research Integrity. Their latest target: A 2015 paper in JAMA, which PETA claims contains inaccurate information.

What’s more, the organization argues, Ringling Bros and Barnum & Bailey Circus — which partly funded the research — is using the findings as “justification for the continued use of abusive training techniques with elephants.” Yesterday, PETA sent a letter to the journal asking it to either retract the paper or issue an expression of concern, claiming: Continue reading JAMA takes all calls for retraction seriously — even from PETA

Cancer researchers: We took data from another lab

1

Authors have admitted to using material from another lab for their paper on neuroblastoma.

A spokesperson for Springer told us that the theft came to light when:

The scientists, from whom the data originated, contacted the journal.

The editor in chief of the journal investigated the case, the spokesperson told us, and then issued this retraction notice:

Continue reading Cancer researchers: We took data from another lab

Cancer paper that doctored image from Science story earns retraction

lungcancercoverHere’s a joke for all you middle-schoolers out there. How are doctored images like bad pennies? They keep cropping up!

Here’s the latest one we’ve picked up: Lung Cancer has retracted a 2014 paper on the genetics of tumors after concluding the authors cribbed a figure that had appeared in a 2005 feature story in Science.

The paper, “ß-elemene against human lung cancer via up-regulation of P53 protein expression to promote the release of exosome,” drew attention on PubPeer last September from a reader who noticed striking similarities between one of the images the authors used and a figure in the Science piece (subscription required). According to the PubPeer commenter: Continue reading Cancer paper that doctored image from Science story earns retraction

Journal flags duplicated text by gynecologic cancer researcher with 13 retractions

cancers-logo

When journals discover duplicated material, many choose to retract — but a cancer journal recently faced with the same dilemma involving a researcher with multiple retractions under his belt has instead decided to flag the paper with an expression of concern.

An editor told us that Cancers considered retracting the paper, by gynecologic cancer researcher Noriyuki Takai, but decided not to because the paper

contains some novel content that is of interest to the scientific community.

“Epigenetic Therapy in Human Choriocarcinoma,” published in 2010, has been cited once, according to Thomson Reuters Web of Science, and self-plagiarizes from other publications by Takai and his co-author, Hisashi Narahara. Both are researchers at Oita University in Japan.

Here’s the expression of concern:

Continue reading Journal flags duplicated text by gynecologic cancer researcher with 13 retractions

How did two papers on same gene with different authors, publishers, end up with identical retraction notices?

1-s2.0-S0006291X16X00058-cov150h1Here’s an interesting case: We’ve found two retracted papers that describe the same gene, and both have nearly identical retraction notices. What’s unusual is that the two papers don’t have any authors in common, and appeared in two different journals published by two different companies.

The cause of both papers’ demise: Plagiarism, and use of unpublished data without permission “from an unnamed source,” who wishes to remain that way. The author of one of the papers confirmed to us that the unnamed source is a “3rd party service company.” Springer told us that the third party in the other paper, however, is another researcher.

It’s a puzzling case, to be sure. We think we have uncovered some of what happened, but remain slightly fuzzy on the details.

Here’s the first retraction, for “KDM3A interacted with p53K372me1 and regulated p53 binding to PUMA in gastric cancer,” originally published online September 30 by Biochemical and Biophysical Research Communications:

Continue reading How did two papers on same gene with different authors, publishers, end up with identical retraction notices?

Mistakes lead to retraction, correction of cancer papers by pair

cover

A series of mistakes have caused a pair of cancer researchers based in China to retract one paper and correct another.

The retraction stems from a duplication of figures in a paper about the molecular underpinnings of colorectal cancer, which the editor of the journal told us he believed was caused by honest error. The other paper was corrected after the authors realized they had published the wrong versions of multiple figures, an error which the authors say does not affect the paper’s conclusions.

This isn’t the first time the pair has had to correct the record — these changes follow a mega-correction for Jie Hong, and Jing-Yuan Fang, both of the Shanghai Jiao-Tong University, where Fang is the director of the Shanghai Institute of Digestive Disease.

Here’s the retraction note for “Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer,” published in the Journal of Pathology:

Continue reading Mistakes lead to retraction, correction of cancer papers by pair

Three HER2-cancer review papers tagged with expressions of concern

The Oncologist Her 2 expression of concern

The Oncologist has tagged three review papers that share a first author with an expression of concern. The three papers, which have together been cited more than 1,000 times, focus on HER2, a gene that can contribute to breast cancer.

Though the papers contain errors, the conclusions — about how the HER2 gene serves as a predictive factor for breast cancer, and a target for therapies — remain unchanged, according to the EOC. The editor of the journal notes that the conclusions of the papers have been confirmed by other publications. Two of the papers are more than 10 years old, and today many patients continue to be treated with medications that target HER2, such as Herceptin.

Here’s the expression of concern:

Continue reading Three HER2-cancer review papers tagged with expressions of concern

DC court allows part of lawsuit against GW to proceed

kumarA DC court has denied part of George Washington University’s motion to dismiss a $8 million lawsuit by a biologist who claims his employer mishandled an investigation into his work.

Last spring, GW filed a motion to dismiss the case, brought forward by Rakesh Kumar, who has three retractions.  A judge has allowed the case to proceed, honoring parts of the school’s motion to dismiss, but denying most of it.

The memorandum opinion gives the specifics:

Continue reading DC court allows part of lawsuit against GW to proceed